BATCH: ac1a07 USER: ck169 DIV: @xyv04/data1/CLS pj/GRP ac/JOB i01/DIV ac0489667 DATE: November 15, 2004

Method for the Determination of Vitamin K Homologues in Human Plasma Using High-Performance Liquid Chromatography-Tandem Mass Spectrometry

Yoshitomo Suhara, Maya Kamao, Naoko Tsugawa, and Toshio Okano*

Department of Hygienic Sciences, Kobe Pharmaceutical University, 4-19-1, Motoyamakita-machi, Higashinada-ku, Kobe 658-8558, Japan

We report here the development of a precise and sensitive method for the determination of vitamin K homologues including phylloquinone (PK), menaquinone-4 (MK-4), and menaquinone-7 (MK-7) in human plasma using HPLC-tandem mass-mass spectrometry with atmospheric pressure chemical ionization (LC-APCI-MS/MS). The method involves the use of stable isotope ^{18}O-labeled internal standard compounds, which were synthesized in our laboratory, and the selection of a precursor and product ion with a MS/MS multiple reaction monitoring method. The average intraassay and interassay variation values for PK, MK-4, and MK-7 were <10%. Average spiked recoveries from authentic compounds added to normal human plasma samples for PK, MK-4, and MK-7 were 98−102%. Mean plasma concentrations of PK, MK-4, and MK-7 from healthy subjects ($n = 20$) were 1.22 ± 0.57, 0.39 ± 0.46, and 6.37 ± 7.45 ng/mL, respectively. We conclude that this novel LC-APCI-MS/MS method should be useful for the evaluation of vitamin K status in postmenopausal women and elderly subjects and provides useful information for the treatment and prevention of osteoporosis with vitamin K.

There is growing interest in the role, biochemical function, and metabolism of vitamin K in vivo. Vitamin K is a blood clotting agent.[1] It serves as an essential cofactor of the carboxylase involved in the activation of the blood coagulation cascade proteins.[2,3] Recent investigations indicate that vitamin K is required for the synthesis of another calcium-binding protein, osteocalcin, which is important for mineralization in bone. To activate calcium-binding proteins, vitamin K participates in the carboxylation of glutamyl residues of osteocalcin to form γ-carboxyglutamyl residues.[4,5] Thus, several of the biological activities of vitamin K homologues such as phylloquinone (PK, vitamin K_1) isolated from green plants, menaquinones (MK-n, vitamin K_2) synthesized by microorganisms, and menadione (vitamin K_3) have been reported. Recently, it was reported that menaquinone-4 (MK-4) was the most potent analogue, and all vitamin K derivatives were converted to MK-4 in vivo.[6,7] In Japan, MK-4 has been given to osteoporotic patients, and phylloquinone has been used as a therapeutic agent for vitamin K-deficient syndromes such as hypoprothronmbinemia in newborn babies and in antibiotic-treated patients. However, information on the physiological and pharmacological roles of vitamin K in vivo is still limited.[8] One reason for this is that the detection and monitoring of vitamin K homologues in plasma and organs have been difficult on account of quite small concentrations and many kinds of impurities even though measurement of the vitamin K plasma concentration is essential to optimize therapy. For pharmacokinetic and epidemiological purposes, specific, accurate, and sensitive analytical methods are required that allow assays at low (ng/mL) plasma levels.

Several assay techniques have been described for the measurement of vitamin K concentrations in human plasma. Initially, high-performance liquid chromatography (HPLC) with ultraviolet (UV) detection was the first choice for measuring the individual forms of vitamin K.[9] This method offered more selectivity than the traditional chick bioassay commonly used to measure vitamin K status; however, its sensitivity was still insufficient. More recent methods include electrochemical techniques, fluorescence detection after postcolumn reduction,[10−13] and gas chromatography-mass spectrometry with HPLC.[14] These techniques provide greater selectivity and sensitivity than UV detection. The most common

* To whom correspondence should be addressed. E-mail: t-okano@kobepharma-u.ac.jp.

(1) Schurgers, L. J.; Dissel, P. E. P.; Spronk, H. M. H.; Soute, B. A. M.; Dhore, C. R.; Cleutjens, J. P. M.; Vermeer, C. *Z. Kardiol. 90*: Suppl. 3 **2001**, III/57−III/63.
(2) Olson, R. E. *Annu. Rev. Nutr.* **1984**, *4*, 281−337.
(3) Suttie, J. W. *Annu. Rev. Biochem.* **1985**, *54*, 459−477.
(4) Hauschka, P. V.; Lian, J. B.; Gallop, P. M. *Proc. Natl. Acad. Sci. U.S.A.* **1975**, *72*, 3925−3929.
(5) Price, P. A.; Otsuka, A. S.; Posner, J. W.; Kristaponis, J.; Rama, N. *Proc. Natl. Acad. Sci. U.S.A.* **1976**, *73*, 1447−1451.
(6) Yamamoto, R.; Komai, M.; Kojima, K.; Furukawa, Y.; Kimura, S. *J. Nutr. Sci. Vitaminol.* **1997**, *43*, 133−143.
(7) Davidson, R. T.; Foley, A. L.; Engelke, J. A.; Suttie, J. W. *J. Nutr.* **1998**, *128*, 220−223.
(8) Tadano, K.; Yuzuriha, T.; Sato, T.; Fujita, T.; Shimada, K.; Hashimoto, K.; Satoh, T. *J. Pharmacobio-Dyn.* **1989**, *12*, 640−645.
(9) Lefevere, M. F.; De Leenheer, A. P.; Claeys, A. E. *J. Chromatogr.* **1979**, *186*, 749−762.
(10) Lambert, W. E., De Leenheer, A. P.; Lefevere, M. F. *J. Chromatogr. Sci.* **1986**, *24*, 76−79.
(11) Shino, M. *Analyst* **1988**, *113*, 393−397.
(12) Hiraike, H.; Kimura, M.; Itokawa, Y. *J. Chromatogr.* **1988**, *43*[illegible]
(13) Wakabayashi, H.; Onodera, K. *Folia Pharmacol. Jpn.* 2000, *11*[illegible]
(14) Dohnikowski, G. G.; Sun, Z.; Grusak, M. A.; Peterson, J. W.[illegible] *Nutr. Biochem.* **2002**, *13*, 168−174.

10.1021/ac0489667 CCC: $30.25
Published on Web 00/00/0000

and conventional method is HPLC-fluorescence detection. For the measurement, naphthoquinone in vitamin K is converted to a hydroquinone analogue by a platinum oxide catalyst or electrochemical reduction after separation by HPLC. Then the hydroquinone, which fluoresces when exposed to ultraviolet light of a wavelength of 320 nm, can be detected with a fluorescence detector with high sensitivity. Most studies about the quantitation of vitamin K in human or rat plasma have been carried out with this method.

We used HPLC-fluorescence detection to measure the concentrations of vitamin K homologues (PK, MK-4, menaquinone-7 (MK-7)) in human plasma and found that PK and MK-7 could be clearly detected as a single peak. However, the peak of MK-4 overlapped with impurities in the plasma and especially appeared in the shoulder of a large peak of impurity. These results indicate that detection of the plasma MK-4 level with this method depends on the threshold, and the accuracy is uncertain. However, it is essential to accurately determine plasma concentrations of vitamin K homologues. If human plasma vitamin K levels could be clearly determined, the data would provide significant information related to applications to clinical trials. For example, investigating the relationship between plasma vitamin K and undercarboxylated osteocalcin levels might elucidate a therapeutic effect for osteoporosis. Furthermore, analyzing the distribution of vitamin K homologues in vivo and their metabolic pathway should provide valuable information for the development of new drugs. Against this background, we evaluated a new method of quantitating plasma vitamin K levels using HPLC-tandem mass-mass spectrometry with atmospheric pressure chemical ionization (LC-APCI-MS/MS) system. One of the advantages of this method is the much greater sensitivity and selectivity in comparison with other LC–MS techniques. In this report, we validated the accuracy and sensitivity of the LC-APCI-MS/MS method using a multiple reaction monitoring mode (MRM) for the determination of vitamin K homologues in human plasma.

EXPERIMENTAL SECTION

Reagents and Chemicals. HPLC-grade solvents and reagents for chemical synthesis were purchased from Nacalai Tesque, Inc. (Kyoto, Japan) and Wako Pure Chemical Industries, Ltd. (Osaka, Japan). The ^{18}O-labeled vitamin K derivatives used as internal standards were synthesized in our laboratory, and the chemical identity of the products was confirmed by nuclear magnetic resonance (NMR) spectrometry and high-resolution MS spectra (HREIMS) (Scheme 1). Control human serum was purchased from Wako Pure Chemical Industries, Ltd.. PK, MK-4, and MK-7, as standard samples, were kindly donated by Eisai Co., Ltd. (Tokyo, Japan).

Preparation of Standard Solutions. A standard mixture (PK, MK-4, MK-7) stock solution of 100 μg/mL for the reference compounds was prepared in ethanol according to the solubility of the solute and stored in the dark at −30 °C prior to use. For the analytical curves, working solutions of the standard mixture, ranging from 25 to 400 ng/mL, were prepared by dilution of the stock solution with ethanol. Stock solutions of 10 μg/mL for ^{18}O-labeled internal standards (PK-^{18}O, MK-4-^{18}O, MK-7-^{18}O) as shown in Scheme 1 were prepared by dilution in ethanol and stored in the dark at −30 °C prior to use. Dilution of the solution with ethanol gave working internal standard solutions of 3.6 and 100 ng/mL, respectively. The 3.6 ng/mL mixture was used for determination of vitamin K homologues in human plasma samples. An equal amount of the standard solution of 25–400 ng/mL and ^{18}O-labeled internal standard solution of 100 ng/mL gave the solution used for the standard curve. The final concentration ranged from 12.5 to 200 ng/mL in the case of the standard and contained 50 ng/mL internal standards.

Scheme 1. Synthetic Route to ^{18}O-Labeled Vitamin K Homologues 1–3 and Their Chemical Yield at Each Step: 1, ^{18}O-Labeled PK; 2, ^{18}O-Labeled MK--4; 3, ^{18}O-Labeled MK-7



Sample Preparation. A liquid control serum (Wako Pure Industries, Ltd., Lot. No. DG118) was used for validation of the LC-APCI-MS/MS method. The serum or donated human plasma (0.5 mL) in a brown screw-capped Pyrex tube was supplemented with 3.6 ng (in 1 mL of ethanol) of PK-^{18}O, MK-4-^{18}O, and MK-7-^{18}O, respectively, as an internal standard. Extra ethanol (1 mL) was then added to denature the protein and 3 mL of hexane was added, followed by shaking for 5 min. The solution was centrifuged at 3000 rpm for 5 min, and the upper layer was separated. The supernatant was applied to Sep-Pak silica (Waters, USA), which was washed with 10 mL of hexane, and then eluted with 5 mL of hexane/diethyl ether (97:3). The eluate was evaporated under reduced pressure. The dried sample was reconstituted in 60 μL of ethanol and vortexed for 10 s. The solutions were transferred to microvials, capped, and placed in a SIL-10AD vp autosampler rack. Aliquots (30 μL) were automatically injected into the HPLC system.

Apparatus and HPLC Conditions. The HPLC analyses were conducted with a Shimadzu HPLC system (Simadzu, Kyoto, Japan) consisting of a binary pump (LC-10AD liquid chromatography), automatic solvent degasser (DGU-14A degasser), and autosampler (SIL-10AD autoinjector). Separations were carried out using a reversed-phase C_{18} analytical column (Capcell PAK C_{18} UG120, 5 μm; 4.6 mm i.d. × 250 mm) (Shiseido, Tokyo, Japan) with a solvent system consisting of an isocratic solvent A (25 min) and then a linear gradient from 0 to 50% ethanol (50 min). Solvent A

Table 1. LC-APCI-MS/MS Parameters

compound	precursor ion (m/z)	collision energy (V)	product ion(s)[a] (m/z)	Rt (min)
MK-4-^{18}O	449.3	29	191.2	20.8
MK-4	445.4	31	187.2	20.8
PK-^{18}O	455.4	35	191.3	41.3
PK	451.3	33	187.1	41.3
MK-7-^{18}O	653.5	39	191.3	74.9
MK-7	649.5	45	187.2	74.9

[a] Ion sequence according to descending abundance.

contained methanol/0.1% acetic acid aqueous (95:5, v/v) and was delivered at 1.0 mL/min. This mobile phase was passed through the column at 1.0 mL/min. The column was maintained at 40 °C with a column oven (CTO-10AC column oven). The HPLC system was controlled by a SCL-10A System Controller (Shimadzu). Acetic acid both functioned as an ion pair reagent during reversed-phase HPLC and facilitated formation of protonated vitamin K, $[M + H]^+$, in the positive ion mode with an APCI. The autosampler was maintained at 25 °C.

Apparatus and Mass Spectrometry. Mass spectrometry was performed with an API3000 LC–MS/MS System (Applied Biosystems, Foster City, CA), equipped with an APCI electrospray interface. All MS data were collected in the positive ion mode, The following settings were used: corona discharge needle voltage, 5.5 kV; vaporizer temperature, 400 °C; sheath gas (high-purity nitrogen) pressure, 50 psi; auxiliary gas, none; and transfer capillary temperature, 220 °C. The electron multiplier voltage was set at 850 eV. Identification and quantitation were based on MS/MS-MRM. The range for the parent scan was 400–500 atomic mass units (amu) in the case of PK, MK-4, and their ^{18}O-labeled compounds and 600–700 amu for MK-7 and MK-7-^{18}O. A complete overview of the MRM transitions, collision energy, retention time, and corresponding segment used for each analyte is given in Table 1.

Quantitation. A quantitative analysis was carried out using MS/MS-MRM of the precursor ion of vitamin K homologues (m/z 445 (MK-4), 449 (MK-4-^{18}O), 451 (PK), 455 (PK-^{18}O), 649 (MK-7), 651 (MK-7-^{18}O)), and their product ion (m/z 187 (natural vitamin K analogues), m/z 191(^{18}O-labeled vitamin K analogues)) with a dwell time of 500 ms. Calibration, using internal standardization, was done by linear regression analysis using five different concentrations, 12.5, 25, 50, 100, and 200 ng/mL. The points were given by the calculated peak area ratio of standard and internal standard.

Precision and Accuracy. Interassay and intraassay precision and accuracy were evaluated using human control serum samples.

Sample Collection. Blood samples (10 mL) were collected into heparinized tubes from a convenient forearm vein. The samples were centrifuged at 2000g for 5 min at room temperature, and the plasma was separated and stored at −30 °C with shading until assay of vitamin K content.

Chemical Synthesis and Data Analysis. The synthetic method and the data on ^{18}O-labeled vitamin K homologues as internal standards are shown in Scheme 1 and described as follows. The data for compounds **5**, **6a**, **6b**, and **6c** were previously reported.[15,16] The 500-MHz ^{1}H NMR spectra of the synthetic compounds were measured on a Varian VXR-500. All compounds were dissolved in deuterized chloroform ($CDCl_3$) (Merk). Chemical shifts are given in ppm (δ) using tetramethylsilane as the internal standard. Mass spectra were registered on a JMS SX-102A instrument. Column chromatography was carried out on silica gel 60 F_{254} (Merk). Unless otherwise noted, all reagents were purchased from commercial suppliers and used as received.

2-Methyl-1,4-naphthalenediol, 1-Acetate (5). Vitamin K_1 monoacetyl derivative **5** was prepared by deacetylation of diacetyl **4** as the reported method.[16, 17] In short, a suspension of diacetate **4** (25.0 g, 97 mmol), K_2CO_3 (4.7 g, 34 mmol), and $Na_2S_2O_4$ (5.0 g, 29 mmol) in 15% aqueous MeOH (300 mL) was kept for 1 h at 30–40 °C with stirring and then poured into 1 L of cold water. The solution was extracted with ethyl acetate (3 × 300 mL), and the organic layers were combined, dried, and concentrated. The residue was purified by silica gel column chromatography using 5:1 hexane/ethyl acetate as eluent and then recrystallized from hexane and ethyl acetate to give **5** (18.8 g) in 90% yield.

4-Acetoxy-3-methyl-2-phytyl-1-naphthaleneol (6a). Phytol (500 mg, 1.7 mmol) was added dropwise to a solution of **5** (250 mg, 1.2 mmol) and $BF_3{\cdot}Et_2O$ (30 μL) in dry dioxane (300 μL) and ethyl acetate (300 μL). Then the mixture was heated to 50 °C for 3 h. The brown reaction mixture was poured into ice-cold water (30 mL) and extracted with ether (3 × 50 mL). The ether extracts were combined and washed with water (25 mL), dried, and concentrated. Purification by flash chromatography using 10:1 hexanes/ethyl acetate as eluent afforded **6a** (266 mg, 47% yield) as a pale yellow oil.

4-Acetoxy-2-geranylgeranyl-3-methyl-1-naphthaleneol (6b). Alcohol **6b** (360 mg, 53% yield) was obtained according to the procedure described above for **6a**.

4-Acetoxy-2-geranylgeranylfarnesyl-3-methyl-1-naphthaleneol (6c). Alcohol **6c** (800 mg, 57% yield) was obtained as described above for **6a**.

2-Methyl-3-phytyl-1,4-dimethoxynaphthalene (7a). A solution of **6a** (400 mg, 809 μmol) in THF (10 mL) was added, using a cannula, to a suspension of 30% potassium hydride, dispersion in mineral oil (128 mg, 3.20 mmol) in THF (20 mL), under argon at 0 °C. An additional 3 mL of THF was used to ensure a complete transfer. The dark green reaction mixture was warmed to room temperature. After 20 min, methyl iodide (230 μL, 3.71 mmol) was added and the mixture was stirred overnight. During this time a white precipitate appeared. The reaction mixture was cooled to 0 °C and quenched by careful addition of saturated aqueous ammonium chloride (10 mL), diluted with water (40 mL), and extracted with ether (4 × 25 mL). The ether layers were combined, dried, filtered, and concentrated to yield 412 mg of **7a** as pale yellow oil. Purification by flash chromatography using 5% ethyl acetate in hexane yielded 346 mg (89% yield) of **7a** as a pale yellow oil: ^{1}H NMR (500 MHz, $CDCl_3$) δ 0.81 (s, 3H), 0.82 (s, 3H), 0.85 (s, 3H), 0.87 (s, 3H), 1.00–1.38 (m, 16H), 1.81 (s, 3H), 1.94–1.98 (m, 2H), 2.38 (s, 3H), 3.57 (dd, J = 1.0, 6.5 Hz, 2H), 3.86 (s, 3H), 3.88 (s, 3H), 5.08–5.11 (m, 1H), 7.44–7.47 (m, 2H), 8.04–8.06 (m, 2H); ^{13}C NMR (125 MHz, $CDCl_3$) δ 12.4, 16.3, 19.7, 22.6, 22.7, 24.5, 24.8, 25.4, 26.3, 28.0, 32.7, 32.8, 36.7, 37.3,

(15) Snyder, C. D.; Rapoport, H. *J. Am. Chem. Soc.* **1974**, *96*, 8046–8054.
(16) Flowers, II, R. A.; Naganathan, S.; Dowd, P.; Arnett, E. M.; Ham, S. W. *J. Am. Chem. Soc.* **1993**, *115*, 9409–9416.
(17) *Jpn. Kokai Tokkyo Koho* 1982; 57140743.

37.4, 39.4, 40.0, 61.3, 62.2, 122.1, 122.3, 122.6, 125.2, 125.4, 126.9, 127.3, 127.5, 131.0, 136.1, 149.7, 150.1; HREIMS calcd for $C_{33}H_{52}{}^{16}O_2$ (M^+), 480.3967, found 480.3967.

2-Methyl-3-geranylgeranyl-1,4-di-methoxynaphthalene (7b). The compound **6b** (70 mg, 143 μmol) was converted to dimethoxynaphthalene (**7b**) (51 mg) in 75% yield as a colorless oil according to the procedure described above for obtaining **7a** from **6a**: ^{1}H NMR (500 MHz, $CDCl_3$) δ 1.56 (s, 3H), 1.57 (s, 3H), 1.59 (s, 3H), 1.67 (s, 3H), 1.82 (s, 3H), 1.92–2.10 (m, 12H), 2.37 (s, 3H), 3.57 (dd, J = 0.5, 6.0 Hz, 2H), 3.86 (s, 3H), 3.88 (s, 3H), 5.06–5.13 (m, 4H), 7.43–7.46 (m, 2H), 8.03–8.06 (m, 2H); ^{13}C NMR (125 MHz, $CDCl_3$) δ 12.4, 15.9, 16.0, 16.4, 17.6, 25.7, 26.3, 26.5, 26.6, 26.7, 39.7, 61.3, 62.1, 122.1, 122.2, 122.8, 124.0, 124.2, 124.4, 125.2, 125.4, 126.9, 127.2, 127.5, 130.9, 131.2, 134.9, 135.1, 135.7, 149.7, 150.1; HREIMS calcd for $C_{33}H_{48}{}^{16}O_2$ (M^+), 474.3498, found 474.3479.

2-Methyl-3-geranylgeranylfarnesyl-1,4-dimethoxynaphthalene (7c). The compound **6c** (80 mg, 101 μmol) was converted to dimethoxynaphthalene (**7c**) (58 mg) in 75% yield as a colorless oil according to the procedure described above for obtaining **7a** from **6a**: ^{1}H NMR (500 MHz, $CDCl_3$) δ 1.57 (s, 6H), 1.59 (s, 12H), 1.67 (s, 3H), 1.82 (s, 3H), 1.92–2.07 (m, 24H), 2.38 (s, 3H), 3.57 (d, J = 7.0 Hz, 2H), 3.87 (s, 3H), 3.88 (s, 3H), 5.06–5.13 (m, 7H), 7.44–7.46 (m, 2H), 8.03–8.06 (m, 2H); ^{13}C NMR (125 MHz, $CDCl_3$) δ 12.4, 16.0, 16.4, 17.7, 25.7, 26.3, 26.6, 26.7, 26.8, 39.7, 61.3, 62.2, 122.1, 122.2, 122.8, 124.0, 124.2, 124.4, 125.2, 125.4, 126.9, 127.2, 127.5, 130.9, 131.3, 134.9, 135.1, 135.7, 149.7, 150.1; HREIMS calcd for $C_{48}H_{76}{}^{16}O_2$ (M^+), 678.5376, found 678.5374.

Phylloquinone-^{18}O (1). A solution of **7a** (60 mg, 124 μmol) in degassed acetonitrile (0.5 mL) and ether (0.1 mL) was added using a cannula to a solution of ceric ammonium nitrate (205 mg, 0.374 mmol) in degassed $H_2{}^{18}O$ (0.1 mL, >95% ^{18}O). An extra 0.3 mL of acetonitrile was used to ensure a complete transfer. After 20 min at room temperature, the reaction mixture was treated with water (10 mL) and ether (10 mL). The aqueous layer was extracted with ether (25 mL), and the ether layers were combined, washed with water (4 × 15 mL), dried, filtered, and concentrated to yield 35 mg (62% yield) of yellow oil. The crude material of **1** was purified by flash chromatography through silica gel using 5% ethyl acetate in hexane as the eluent. Analysis of LC-APCI-MS/MS showed a 95.5% incorporation of ^{18}O; ^{13}C NMR showed 95.3% labeling: ^{1}H NMR (500 MHz, $CDCl_3$) δ 0.81 (s, 3H), 0.82 (s, 3H), 0.83 (s, 3H), 0.87 (s, 6H), 0.98–1.41 (m, 16H), 1.78 (s, 3H), 1.92–1.96 (m, 2H), 2.20 (s, 3H), 3.37 (d, J = 7.0 Hz, 2H), 5.01 (dt, J = 1.0, 7.0 Hz, 1H), 7.67–7.71 (m, 2H), 8.06–8.10 (m, 2H); ^{13}C NMR (125 MHz, $CDCl_3$) δ 12.7, 16.3, 19.7, 22.6, 22.7, 24.4, 24.5, 24.8, 25.3, 26.0, 28.0, 32.6, 32.8, 36.6, 37.3, 37.4, 39.4, 40.0, 118.8, 126.2, 126.3, 132.16, 132.20, 133.26, 133.32, 138.0, 143.3, 146.2, 184.5, 185.4; HREIMS calcd for $C_{31}H_{46}{}^{18}O_2$ (M^+), 454.3583, found 454.3588.

Menaquinone-4-^{18}O (2). The compound **7b** (70 mg, 147 μmol) was converted to menaquinone-4 (**2**) (40 mg) in 60% yield as a pale yellow oil according to the procedure described above for obtaining **1** from **7a**: ^{1}H NMR (500 MHz, $CDCl_3$) δ 1.55 (s, 3H), 1.56 (s, 3H), 1.59 (s, 3H), 1.67 (s, 3H), 1.79 (s, 3H), 1.91–2.09 (m, 12H), 2.19 (s, 3H), 3.37 (d, J = 7.5 Hz, 2H), 5.00–5.10 (m, 4H), 7.67–7.70 (m, 2H), 8.06–8.10 (m, 2H); ^{13}C NMR (125 MHz, $CDCl_3$) δ 12.7, 15.95, 16.01, 16.4, 17.7, 25.7, 26.0, 26.5, 26.6, 26.7, 39.7, 119.1, 123.9, 124.2, 124.4, 126.2, 126.3, 131.2, 132.2, 133.26, 133.32, 134.9, 135.2, 137.6, 143.3, 146.2, 184.5, 185.4; HREIMS calcd for $C_{31}H_{40}{}^{18}O_2$ (M^+), 448.3113, found 448.3111.

Menaquinone-7-^{18}O (3). The compound **7c** (80 mg, 118 μmol) was converted to menaquinone-4 (**3**) (42 mg) in 55% yield as a pale yellow oil according to the procedure described above for obtaining **1** from **7a**: ^{1}H NMR (500 MHz, $CDCl_3$) δ 1.56 (s, 6H), 1.59 (s, 12H), 1.67 (s, 3H), 1.79 (s, 3H), 1.91–2.09 (m, 24H), 2.19 (s, 3H), 3.37 (d, J = 7.0 Hz, 2H), 5.00–5.13 (m, 7H), 7.67–7.70 (m, 2H), 8.07–8.09 (m, 2H); ^{13}C NMR (125 MHz, $CDCl_3$) δ 12.7, 15.95, 16.01, 16.4, 17.7, 25.7, 26.0, 26.5, 26.6, 26.7, 26.8, 39.7, 119.1, 123.9, 124.2, 124.4, 126.2, 126.3, 131.2, 132.2, 133.27, 133.28, 134.9, 135.2, 137.6, 143.4, 146.2, 184.5, 185.5; HREIMS calcd for $C_{46}H_{64}{}^{18}O_2$ (M^+), 652.4991, found 652.4984

RESULTS AND DISCUSSION

Method Development. The separation of vitamin K derivatives and the respective internal standards in human plasma was achieved in 80 min. After a wash of the column and reequilibration period of 40 min, the next sample was injected. The reliability of the LC method was evaluated based on the variation in retention times. The relative standard deviation (RSD), calculated from retention times obtained from over 30 injections, proved to be less than 1.0% for all compounds, indicating good chromatographic stability.

The precursor and product ion(s) for each analyte of interest was determined by the direct infusion of single-analyte solutions (1 μg/mL in ethanol). After optimization of the separation process and selection of a unique precursor–product ion combination for each compound, a quantitative LC-APCI-MS/MS method was developed based on MRM.

To ensure maximum sensitivity in the MS analysis, the chromatographic run was divided into seven segments. Each segment was optimized for the compounds of interest eluted within a given time period. The following mass spectrometric parameters were specified within each segment: transfer capillary voltage, tube lens voltage, ion optic voltage, collision energy, and MRM scan events. Table 1 shows an overview of the MS parameters including MRM transitions, collision energy, and retention time. The MRM chromatograms for the target analytes were obtained from the injection of a standard mixture (10 ng). The retention times of the standard and internal standard peaks completely matched; namely, this result proved that the compounds had the same chemical properties.

^{18}O-Labeled Internal Standards. As a preliminary experiment, we tried to detect PK and MK-n (n= 1–10) in several human plasma samples using LC-APCI-MS/MS. PK, MK-4, and MK-7 were found as major peaks. Therefore, we chose stable isotope-labeled vitamins as internal standards to measure these three kinds of vitamin K. The stable isotopes are nonradioactive forms of elements that occur naturally within the environment and have applications for human research. There has been much recent study using stable isotope-labeled vitamins and provitamins, such as [$^2H_7$]MK-4 (deuterated MK-4) and [$^2H_7$]PK (deuterated PK), to examine metabolic pathways in vitro and in vivo using mass spectrometry.[14,18] We used isotope ^{18}O-labeled vitamin K

(18) Sano, Y.; Kikuchi, K.; Tadano, K.; Hoshi, K.; Koshihara, Y. *Anal. Sci.* **1997**, *13*, 67–73.

analogues as internal standards, namely, MK-4-^{18}O, PK-^{18}O, and MK-7-^{18}O.[19,20] The efficiency of extraction can be adjusted accurately since the chemical properties of the labeled analogues are almost the same as those of the original substrates. The synthesis of the requisite ^{18}O-labeled vitamin K homologues was carried out as shown in Scheme 1. These analogues are much easier and more convenient to synthesize than, for example, deuterated vitamin K. First, we chose monoacetate **4** to afford a coupling intermediate with an alkyl side chain, though there are many different schemes for the synthesis of vitamin K derivatives.[15,21] The compound **5** was prepared from 1,4-hydroquinone diacetate **4** by selective hydrolysis of 4-*O*-acetate with sodium hydrosulfite.[16,17] Treatment of the monoacetate **5** with an alkyl side chain alcohol (phytol, geranylgeraniol, geranygeranylfarnesol) in the presence of boron trifluoride etherate yielded **6a**–**6c** as reported.[16] To afford the dimethyl ether **7a**–**7c**, the monocetate **5** was treated with an excess amount of potassium hydride followed by methyl iodide to give **7a**–**7c** in good yield. Finally, oxidation of the naphthohydroquinone methyl ether **5** with Ce$(NH_4)_2(NO_3)_6$ in $H_2{}^{18}O$ gave the desired ^{18}O-labeled vitamin K homologues **1**–**3** in good yield. Thus, three kinds of stable isotope-labeled compounds were prepared for LC-APCI-MS/MS detection.

Calibration and Validation. Calibration using internal standardization with standard samples and ^{18}O-labeled analogues was performed. Under the stated conditions, stock solutions proved to be stable for at least 3 months. Analyte recoveries in the stability experiments were within the variability range obtained for precision and accuracy. No significant loss or deterioration of any of the compounds of interest was observed. Analytes were stable during sample pretreatment at room temperature.

The method fulfilled our analytical standard criteria. MRM provided high specificity for all of the compounds, and no cross-talk interference with the ^{18}O-labeled internal standards was observed. The positive precursor ion APCI-MS of PK, MK-4, MK-7, and their ^{18}O-labeled forms showed base peaks at m/z 451, 445, 649, 455, 449, and 653 corresponding to protonated molecules, respectively. While the product ion of PK, MK-4, and MK-7 was m/z 187, that of their labeled analogues was m/z 191.[22] Each of the calibration curves could be drawn as linear through zero. All values were calculated as ratios (intensity of analyte area)/(that of internal standard area). Over the range of vitamin K concentrations, 12.5–200 ng/mL, positive ion APCI produced a linear response and the each correlation coefficient of the calibration curves in PK, MK-4, and MK-7 were 0.9993, 0.9997, and 0.9999. LC-APCI-MS/MS was used throughout this investigation because of its wide dynamic range and linearity of detector response. Thus, vitamin K could be directly detected without conversion to other derivatives.

Figure 1 shows the MRM chromatograms for the target analytes obtained from the injection of human plasma samples. We examined recovery and accuracy using commercially available pooled plasma. The injection samples were obtained according to the procedure described above. All measurements were well performed, and each peak of the vitamin K analogues was clearly afforded as a single peak.



Figure 1. LC-APCI-MS/MS chromatograms of the analytes of vitamin K Homologues for the injection of (i) standard mixture and (ii) human plasma sample with internal standards. PK, phylloquinone; MK-4, menaquinone-4; MK-7, menaquinone-7; PK-^{18}O, ^{18}O-labeled phylloquinone; MK-4-^{18}O, ^{18}O-labeled menaquinone-4; MK-7-^{18}O, ^{18}O-labeled menaquinone-7.

After the analytes were extracted from 0.5 mL of plasma sample including 3.6 ng/mL internal standard, they were concentrated to 60 μL in an ethanol solution. The concentrations of both internal standards in the samples and calibration curves were 50 ng/mL. The data were converted to the concentration in 1 mL of plasma according to the following equation: vitamin K in plasma concentration (ng/mL) = measured data × (6/5) × (60/500).

As shown in Table 2, the average intraassay and interassay variation (RSD) for PK, MK-4, and MK-7 was less than 10%. Average spiked recoveries from authentic compounds (PK, 0.95 ± 0.04 ng/mL; MK-4, 0.27 ± 0.01 ng/mL; MK-7, 1.44 ± 0.08 ng/mL) added to normal human pool serum samples for PK, MK-4, and MK-7 were 98–102%. With this method, the lower quantitation limits were less than 0.1 ng/mL (PK, 40 pg/mL; MK-4, 50 pg/mL; MK-7, 80 pg/mL). The quantitation limits of plasma vitamin K concentrations are different from species. Indeed, the signal-to-noise ratio depends on impurities in plasma samples. As far as we know, the rat plasma or serum vitamin K concentrations were easy to determine in comparison with human plasma because

(19) Nagamathan, S.; Hershline, R.; Ham, S. W.; Dowd, P. *J. Am. Chem. Soc.* **1994**, *116*, 9831–9839.
(20) Dowd, P.; Ham, S.-W.; Hershline, R. *J. Am. Chem. Soc.* **1992**, *114*, 7613–7617.
(21) Naruta, Y. *J. Org. Chem.* **1980**, *45*, 4097–4104.
(22) Di Mari, S. J.; Supple, J. H.; Rapoport, H. *J. Am. Chem. Soc.* **1966**, *88*, 1226–1232.

Table 2. Summary of Assay Method for Vitamin K[a]

		PK	MK-4	MK-7
quantitation limit (pg/mL)		40	50	80
recovery	mean ± SD (ng/mL)	1.89 ± 0.05	0.43 ± 0.02	3.19 ± 0.20
	RSD (%)	2.65	4.65	6.27
	recovery (%)	98 ± 3	102 ± 5	102 ± 6
intraassay control serum	mean ± SD (ng/mL)	0.95 ± 0.04	0.27 ± 0.01	1.44 ± 0.08
	RSD (%)	6.21	4.79	5.85
interassay control serum	mean ± SD (ng/mL)	1.03 ± 0.06	0.21 ± 0.02	1.51 ± 0.04
	RSD (%)	6.21	9.10	2.97

[a] Recovery, intraassay, and interassay: $n = 5$.



Figure 2. Comparison of assayed values (ng/mL) of human plasma vitamin K homologues between the LC-APCI-MS/MS method (MS method) and HPLC with fluorescence detection (fluorescence method). (A) MK-4 (normal subjects); (B) MK-4 (osteoporotic patients); (C) PK (normal subjects and osteoporotic patients); (D) MK-7 (normal subjects and osteoporotic patients).

impurities were not observed (data are not shown). These results proved our system was reliable and reproducible for the measurement of plasma vitamin K.

Plasma Concentration Profile of Vitamin K Analogues. Next we examined healthy subjects ($n = 20$) using this method. The accuracy of determination was improved according to the internal standards. The mean plasma concentrations of PK, MK-4, and MK-7 from the subjects were 1.22 ± 0.57, 0.39 ± 0.46, and 6.37 ± 7.45 ng/mL, respectively. While plasma levels of vitamin K analogues in osteoporotic patients on a MK-4 supplement were 1.90 ± 0.78, 172.90 ± 138.56, and 7.03 ± 5.79 ng/mL.

To compare the conventional fluorescence method and LC-APCI-MS/MS detection, we examined another 27 plasma samples using both methods. The concentrations of PK and MK-7 correlated although the fluorescence method gave slightly higher concentrations than the LC-APCI-MS/MS method as shown in Figure 2C and D. However, the plasma levels of MK-4 were not related at all. We also examined 17 plasma samples from osteoporotic patients given an MK-4 supplement. The concentrations of all vitamin K derivatives were correlated to some extent (Figure 2B–D). This result suggested that the detection of MK-4 using these methods was not related to the low concentration range (less than 1.0 ng/mL) (Figure 2A) but correlated with the higher concentration range (Figure 2B). Presumably, impurities in the plasma sample are at least partly responsible for the result.

Our LC-APCI-MS/MS system has much greater sensitivity and selectivity in comparison with the conventional method. As we described above, the conventional method has various disadvantages such as interference from impurities in human plasma and correction of extractive efficiency. Most conventional methods do not use any internal standards or often use another kind of vitamin K homologue. Extractive efficiency is important for accurate

determination of plasma concentration. In our method, extractive efficiency from plasma can be completely adjusted using ^{18}O-labeled vitamin K analogues as internal standards, which have the same chemical properties as the original vitamin K homologues. Therefore, the accuracy of determination was remarkably improved. Though the conventional method is certainly a common system, our method is useful to make gold standards of plasma vitamin K concentrations.

CONCLUSION

This study shows that LC-APCI-MS/MS provides a rapid and relatively easy-to-use approach to the quantitation of vitamin K analogues in human plasma without compromising assay sensitivity. This approach overcame major disadvantages of previous methods. For the analysis of both the analyte and internal standard, the method has been thoroughly validated. The sensitivity has been shown to be excellent, with no interference from impurities. The interday precision for the analyte was less than 10% RSD. Furthermore, throughout our study, the HPLC column used remained stable.

We conclude that this novel LC-APCI-MS/MS method using ^{18}O-labeled internal standards should be convenient for the evaluation of vitamin K status in human plasma; therefore, the data will provide useful information for the treatment and prevention of osteoporosis with vitamin K.

ACKNOWLEDGMENT

We thank Dr. Masataka Shiraki, the Research Institute and Practice for Involutional Disease. We are also grateful to Eisai Co., Ltd. for the gift of vitamin K standards. This work was supported in part by a Grant-in-Aid for Comprehensive Research on Cardiovascular Diseases and the Research on the Dietary Reference Intakes in Japanese from the Ministry of Health, Labor and Welfare of Japan.

SUPPORTING INFORMATION AVAILABLE

Calibration curves for vitamin D homologues. This material is available free of charge via the Internet at http://pubs.acs.org.

Received for review July 14, 2004. Accepted October 8, 2004.

AC0489667

DTD 5

Available online at www.sciencedirect.com

SCIENCE DIRECT®

Journal of Chromatography B, xxx (2004) xxx–xxx

JOURNAL OF CHROMATOGRAPHY B

www.elsevier.com/locate/chromb

Determination of plasma Vitamin K by high-performance liquid chromatography with fluorescence detection using Vitamin K analogs as internal standards

Maya Kamao, Yoshitomo Suhara, Naoko Tsugawa, Toshio Okano*

Department of Hygienic Sciences, Kobe Pharmaceutical University, 4-19-1 Motoyamakita-machi, Higashinada-ku, Kobe 658-8558, Japan

Received 8 July 2004; accepted 2 November 2004

Abstract

A HPLC fluorescence determination method for Vitamin K derivatives (Vitamin K_1, phylloquinone, PK and K_2, menaquinones, MK-4 and MK-7) using post-column reduction and internal standards was developed. Selectivity and reproducibility were increased by optimized chromatography conditions and satisfactory precision and accuracy were attained by using synthetic internal standards. After addition of internal standards to plasma samples, lipids were extracted with ethanol and hexane. Chromatography was performed by isocratic reverse phase separation on a C18 column. Vitamin K derivatives were detected at 430 nm with excitation at 320 nm for MK-4 and 240 nm for PK and MK-7. The detection limits for MK-4, PK and MK-7 were 4, 2 and 4 pg, respectively. The recoveries of MK-4, PK and MK-7 were greater than 92% and the inter- and intra-assay R.S.D. values were 5.7–9.2% for MK-4, 4.9–9.6% for PK and 6.3–19.3% for MK-7. The data showed good correlation between proposed method and LC-APCI/MS method for MK-4 ($R^2 = 0.988$), PK ($R^2 = 0.979$) and MK-7 ($R^2 = 0.986$). The method allows the determination of Vitamin K for evaluating their clinical and nutritional status.

Keywords: Vitamin K; Internal standards; Fluorescence detection

1. Introduction

Vitamin K is a cofactor for an enzyme that converts specific glutamyl residues in several proteins such as plasma clotting factors II (prothrombin), VII, IX and X, protein C, S and Z, osteocalcin (bone Gla protein), matrix Gla protein to γ-calboxylglutamyl (Gla) residues. These Vitamin K-dependent proteins play crucial roles in homeostasis and calcification [1,2]. It is well known that neonatal and infantile Vitamin K deficiency causes melena neonatorum and intracranial hemorrhagic disorders. In addition, several reports indicate an important role for Vitamin K in bone health. Administration of Vitamin K results in an increase in bone-mineral density and a reduction in bone resorption in humans [3–6] and rodents [7–13].

There are two major forms of Vitamin K in nature. Vitamin K_1 (phylloquinone, PK) is produced by plants and algae, and Vitamin K_2 series (menaquinones, MKs) is synthesized by bacteria (Fig. 1). The length of the isoprenoid side-chain in menaquinones is defined by its carbon number, or the number of isoprenoid units. The major dietary form of Vitamin K has been considered to be PK, which is contained in green and leafy vegetables [14,15]. In contrast, MKs are found in fermented food and in the colon, where they are synthesized by the intestinal microflora [16]. However, little is known about Vitamin K status in humans. It is difficult to determine plasma Vitamin K because basal concentrations of Vitamin K in plasma are very low. In addition, MK-4 has received governmental approval for use as an agent for the treatment of osteoporosis in Japan. Thus, measurement of MK-4

* Corresponding author. Tel.: +81 78 441 7563; fax: +81 78 441 7565.
E-mail address: t-okano@kobepharma-u.ac.jp (T. Okano).

1570-0232/$ – see front matter © 2004 Published by Elsevier B.V.
doi:10.1016/j.jchromb.2004.11.003



Fig. 1. Structures of natural Vitamin K_1, K_2 and internal standards.

concentration in plasma of osteoporotic patients is important in therapeutic drug monitoring.

Previously, several methods for separation and determination of Vitamin K by thin layer chromatography (TLC) [17], gas liquid chromatography (GLC) [18,19] and high-performance liquid chromatography (HPLC) with ultraviolet (UV) detection [20], fluorescence detection [21–25], electrochemical detection [26–29] and mass spectrometric detection [30] were reported. Recently, we have developed a method for the determination of Vitamin K in human plasma by liquid chromatograpy-atmospheric pressure chemical ionization/mass spectrometry (LC-APCI/MS) [31]. Although this method has great advantage in high sensitivity and accuracy, it is very expensive for routine assay. In contrast, the separation and detection by HPLC with fluorescence detection using post-column chemical reduction is relatively high sensitive, convenient and stable. Vitamin Ks are reduced by the platinum-reduction column and converted into Vitamin K hydroquinones, which are highly fluorescent. However, there is still the problem in separation of Vitamin K from interfering compounds in plasma. Especially, it is difficult to determine MK-4 accurately in a routine assay, because basal plasma concentration of MK-4 is markedly lower than PK and elute at the same retention time of a number of interfering compounds in plasma. Also, it is assumed that use of internal standards is necessary due to the loss of Vitamin K during extraction. One of natural Vitamin K derivatives, MK-6, has been used widely as internal standard [32], because human circulating levels are undetectable. However, synthetic compounds are more suitable for internal standards in terms of application to various samples such as animal tissue or foods. In this paper, we describe improved highly sensitive assay method for Vitamin K in human plasma using two kinds of HPLC systems, optimized for determination of MK-4 and less polar derivatives, PK and MK-7. We also synthesized Vitamin K analogs with different length of the alkyl side-chain (Fig. 1) as internal standards and selected suitable synthetic Vitamin K analogs for determination of MK-4, PK and MK-7.

2. Experimental

2.1. Chemicals and reagents

PK, MK-4, MK-5, MK-6, MK-7, MK-8, MK-9 and MK-10 were kindly provided by Eisai Pharmaceuticals (Tokyo, Japan). The Vitamin K analogs with different length of the alkyl side-chain as internal standards were synthesized in our laboratory as described below. ^{18}O-labeled MK-4, PK and MK-7 which are replaced both oxygen atoms at quinone structure to ^{18}O were also synthesized in our laboratory as described previously [31]. The isotopic purity of ^{18}O-labeled MK-4, PK and MK-7 are 95%, respectively. HPLC-grade solvents and reagents for chemical synthesis were purchased from Nacalai Tesque, Inc. (Kyoto, Japan) and Wako Pure Chemical Industries Ltd. (Osaka, Japan). Control human serum was purchased from Wako Pure Chemical Industries Ltd. (Osaka, Japan).

2.2. Synthesis of internal standards

The synthetic method of Vitamin K analogs with different length of the alkyl side-chain was previously reported [33]. A solution of 1 g $(NH_4)_2S_2O_8$ in 10 mL water was added dropwise over 90–120 min to a stirred suspension of 10 mL water, 20 mL acetonitrile, 0.25 g $AgNO_3$, 0.2 g Vitamin K_3 (2-methyl-1,4-naphthoquinone) and 1.5 mmol fatty acid ($n = 13$, 14, 15, 16, 18, 19, 20, 23) at 65–75 °C. After stirring for another 30 min, the resulting mixture was cooled, extracted with ether, washed with water, dried, filtered, and concentrated. Purified products with yield of 50–65% as yellow needles were obtained after flash chromatography through silica gel 60 (Merck, Darmstadt, Germany) using hexane-ethyl acetate (20:1, v/v) and recrystallization. The 500 MHz ^1H NMR spectra of the synthetic compounds were measured on a Varian VXR-500. All compounds were dissolved in 0.3 mL of deuterated chloroform ($CDCl_3$, Merk). Chemical shifts are given in ppm (δ) using tetramethylsilane (TMS) as the internal standard. Mass spectra were obtained using M-4100 (Hitachi, Tokyo, Japan).

2.2.1. 2-Methyl-3-trydecyl-1,4-naphthoquinone (Code: I.S.-C13)

^1H NMR (500 MHz, $CDCl_3$) δ 0.88 (t, $J = 6.8$, 3H), 1.15–1.38 (m, 16H), 1.40 (m, 2H), 1.47 (m, 2H), 1.57 (m, 2H), 2.19 (s, 3H), 2.63 (t, $J = 7.8$, 2H), 7.69 (m, 2H), 8.08 (m, 2H); ^{13}C NMR (125 MHz, $CDCl_3$) δ 12.63, 14.11, 22.68, 27.10, 28.76, 29.34, 29.43, 29.53, 29.62, 29.63, 29.66, 29.99, 31.91,

126.15, 126.25, 132.16, 132.21, 133.26, 133.29, 143.07, 147.59, 184.72, 185.40; HREIMS calcd for $C_{24}H_{34}O_2$ (M^+), 354.2559, found 354.2561.

2.2.2. 2-Methyl-3-tetradecyl-1,4-naphthoquinone (Code: I.S.-C14)

^{1}H NMR (500 MHz, $CDCl_3$) δ 0.88 (t, J=7.0, 3H), 1.15–1.38 (m, 18H), 1.40 (m, 2H), 1.47 (m, 2H), 1.57 (m, 2H), 2.19 (s, 3H), 2.63 (t, J=7.8, 2H), 7.69 (m, 2H), 8.08 (m, 2H); ^{13}C NMR (125 MHz, $CDCl_3$) δ12.63, 14.11, 22.68, 27.10, 28.76, 29.34, 29.43, 29.54, 29.62, 29.64, 29.65, 29.68, 30.00, 31.91, 126.15, 126.25, 132.16, 132.21, 133.26, 133.29, 143.07, 147.59, 184.72, 185.40; HREIMS calcd for $C_{25}H_{36}O_2$ (M^+), 368.2715, found 368.2717.

2.2.3. 2-Methyl-3-pentadecyl-1,4-naphthoquinone (Code: I.S.-C15)

^{1}H NMR (500 MHz, $CDCl_3$) δ 0.88 (t, J=6.8, 3H), 1.15–1.38 (m, 20H), 1.40 (m, 2H), 1.47 (m, 2H), 1.57 (m, 2H), 2.19 (s, 3H), 2.63 (t, J=7.8, 2H), 7.69 (m, 2H), 8.08 (m, 2H); ^{13}C NMR (125 MHz, $CDCl_3$) δ 12.63, 14.11, 22.68, 27.10, 28.76, 29.35, 29.43, 29.54, 29.62, 29.64, 29.66, 29.67, 29.69, 30.00, 31.91, 126.15, 126.25, 132.16, 132.21, 133.26, 133.29, 143.07, 147.59, 184.72, 185.40; HREIMS calcd for $C_{26}H_{38}O_2$ (M^+), 382.2872, found 382.2866.

2.2.4. 2-Methyl-3-hexadecyl-1,4-naphthoquinone (Code: I.S.-C16)

^{1}H NMR (500 MHz, $CDCl_3$) δ 0.88 (t, J=6.8, 3H), 1.15–1.38 (m, 22H), 1.40 (m, 2H), 1.47 (m, 2H), 1.57 (m, 2H), 2.19 (s, 3H), 2.63 (t, J=7.8, 2H), 7.69 (m, 2H), 8.08 (m, 2H); ^{13}C NMR (125 MHz, $CDCl_3$) δ 12.63, 14.12, 22.69, 27.11, 28.76, 29.35, 29.43, 29.54, 29.63, 29.65, 29.66, 29.67, 29.68, 29.69, 30.00, 31.91, 126.16, 126.26, 132.16, 132.21, 133.26, 133.30, 143.07, 147.60, 184.73, 185.41; HREIMS calcd for $C_{27}H_{40}O_2$ (M^+), 396.3028, found 396.3025.

2.2.5. 2-Methyl-3-octadecyl-1,4-naphthoquinone (Code: I.S.-C18)

^{1}H NMR (500 MHz, $CDCl_3$) δ 0.88 (t, J=6.8, 3H), 1.15–1.38 (m, 26H), 1.40 (m, 2H), 1.47 (m, 2H), 1.57 (m, 2H), 2.19 (s, 3H), 2.63 (t, J=7.8, 2H), 7.69 (m, 2H), 8.08 (m, 2H); ^{13}C NMR (125 MHz, $CDCl_3$) δ 12.63, 14.11, 22.68, 27.11, 28.76, 29.35, 29.43, 29.54, 29.62, 29.64, 29.65, 29.66, 29.69, 30.00, 31.92, 126.16, 126.26, 132.16, 132.21, 133.26, 133.29, 143.07, 147.59, 184.72, 185.40; HREIMS calcd for $C_{29}H_{44}O_2$ (M^+), 424.3341, found 424.3344.

2.2.6. 2-Methyl-3-nonadecyl-1,4-naphthoquinone (Code: I.S.-C19)

^{1}H NMR (500 MHz, $CDCl_3$) δ 0.88 (t, J=6.8, 3H), 1.15–1.38 (m, 28H), 1.40 (m, 2H), 1.47 (m, 2H), 1.56 (m, 2H), 2.19 (s, 3H), 2.63 (t, J=7.8, 2H), 7.69 (m, 2H), 8.08 (m, 2H); ^{13}C NMR (125 MHz, $CDCl_3$) δ 12.63, 14.12, 22.69, 27.11, 28.77, 29.36, 29.43, 29.55, 29.63, 29.65, 29.67, 29.68, 29.69, 30.00, 31.92, 126.16, 126.26, 132.16, 132.21, 133.26, 133.30, 143.07, 147.60, 184.73, 185.41; HREIMS calcd for $C_{30}H_{46}O_2$ (M^+), 438.3498, found 438.3497.

2.2.7. 2-Methyl-3-icosyl-1,4-naphthoquinone (Code: I.S.-C20)

^{1}H NMR (500 MHz, $CDCl_3$) δ 0.88 (t, J=7.0, 3H), 1.15–1.38 (m, 30H), 1.40 (m, 2H), 1.47 (m, 2H), 1.57 (m, 2H), 2.19 (s, 3H), 2.63 (t, J=7.8, 2H), 7.69 (m, 2H), 8.08 (m, 2H); ^{13}C NMR (125 MHz, $CDCl_3$) δ 12.63, 14.11, 22.69, 27.11, 28.76, 29.35, 29.43, 29.54, 29.63, 29.65, 29.66, 29.68, 29.69, 30.00, 31.92, 126.16, 126.26, 132.16, 132.21, 133.26, 133.30, 143.07, 147.60, 184.73, 185.41; HREIMS calcd for $C_{31}H_{48}O_2$ (M^+), 452.3654, found 452.3658.

2.2.8. 2-Methyl-3-tricosyl-1,4-naphthoquinone (Code: I.S.-C23)

^{1}H NMR (500 MHz, $CDCl_3$) δ 0.88 (t, J=6.8, 3H), 1.15–1.38 (m, 36H), 1.40 (m, 2H), 1.47 (m, 2H), 1.55 (m, 2H), 2.19 (s, 3H), 2.63 (t, J=7.8, 2H), 7.69 (m, 2H), 8.08 (m, 2H); ^{13}C NMR (125 MHz, $CDCl_3$) δ 12.63, 14.11, 22.65, 27.11, 28.76, 29.35, 29.43, 29.54, 29.63, 29.65, 29.67, 29.68, 29.69, 30.00, 31.92, 126.16, 126.27, 132.18, 132.23, 133.26, 133.30, 143.08, 147.61, 184.73, 185.41; HREIMS calcd for $C_{34}H_{54}O_2$ (M^+), 494.4124, found 494.4126.

2.3. Sample preparation

For the developmental work on the assay, control serum (Wako Pure Chemical Industries Ltd.) and plasma of healthy subjects were used. The plasma samples from healthy subjects and osteoporotic patients treated with MK-4 were obtained through the kind help of Dr. M. Shiraki, the Research Institute and Practice for Involutional Disease. Exactly 0.5 mL of serum or plasma sample was placed in a brown tube and diluted with distilled water to 1 mL. After addition of internal standards solution (I.S.-C16 and I.S.-C19, 1 ng/50 μL each), the diluted sample was extracted with 1.9 mL of ethanol and 3 mL of hexane. The mixture was shaken for 5 min before centrifuging at 3000 rpm for 5 min, 2.5 mL of hexane layer was passed through a Sep-Pak silica cartridge (Waters, Milford, MA, USA) that was washed with 10 mL of hexane. Vitamin K was eluted with 5 mL of hexane-diethyl ether (97:3). The eluate was evaporated under reduced pressure, and the residue was dissolved with 200 μL of ethanol. Forty microlitre aliquots were subjected to two kinds of HPLC, System 1 for determination of MK-4 and System 2 for determination of PK and MK-7. The recoveries of MK-4, PK and MK-7 were evaluated using control serum spiked MK-4 (0.1, 0.2 or 0.4 ng/0.5 mL serum), PK (0.4, 0.8 or 1.6 ng/0.5 mL serum) and MK-7 (0.75, 1.5 or 3.0 ng/0.5 mL serum) (n=5). To evaluate the precision (intraassay and interassay), control serum and plasma of healthy subject were used. To examine the correlation with LC-APCI/MS method, plasma samples from healthy subjects (n=20, age 59–82) and osteoporotic patients treated with MK-4 (n=10; age, 47–85; daily dose of MK-4, 45 mg; attending period, 4.0–12.2 years)

were used. For LC-APCI/MS analyses, ^{18}O-labeled MK-4, PK and MK-7 were used as internal standards.

2.4. HPLC apparatus and conditions for fluorescence detection

The HPLC system consisted of a LC-10AD$_{VP}$ pump (Shimadzu, Kyoto, Japan), a SIL-10AD$_{VP}$ auto injector (Shimadzu), a CTO-10AD$_{VP}$ column oven (Shimadzu) set to 35 °C, and a RF-10A$_{XL}$ fluorescence detector set to an excitation wavelength of 320 nm (System 1: for determination of MK-4) or 240 nm (System 2: for determination of PK and MK-7) and an emission wavelength of 430 nm. The data acquired by C-R8A chromatopac (Shimadzu) were processed by CLASS-PR10 software (Shimadzu). Separations were performed on a CAPCELL PAK C18 UG120 (4.6 mm × 250 mm, 5 μm, Shiseido Co. Ltd., Tokyo, Japan). A RC-10 platinum-reduction column (4.0 mm × 15 mm, Irica, Kyoto, Japan) was located between HPLC column and the fluorescence detector for postcolumn reduction.

Analysis was performed using an isocratic eluent system. For determination of MK-4, the mobile phase was a 95:5 (v/v) mixture of methanol and water (System 1). For determination of PK and MK-7, the mobile phase was a 95:5 (v/v) mixture of methanol and ethanol (System 2). The flow-rate was 1.0 mL/min in both systems.

For determination of MK-4, standard solutions containing MK-4 (1, 5 and 10 ng/mL), and I.S.-C16 (5 ng/mL) were used. For determination of PK and MK-7, standard solutions containing PK and MK-7 (1, 5 and 10 ng/mL each), and I.S.-C19 (5 ng/mL) were used. The calibration curve was constructed by plotting the peak-area ratio of Vitamin K to internal standard versus molar ratio of Vitamin K to internal standard. The concentration of MK-4, PK and MK-7 in plasma (ng/mL) was calculated using the following formula:

$$\text{Concentration of MK-4, PK or MK-7} = \frac{RS}{V}$$

where R is quantitative ratio of Vitamin K to internal standard obtained from calibration curve, S is added amount of internal standards (1 ng), V is volume of a sample (mL) taken for assay (0.5 mL).

2.5. LC-APCI/MS apparatus and conditions

The HPLC system consisted of a SCL-10ADvp system controller (Shimadzu), a LC-10AD$_{VP}$ pump (Shimadzu), DGU-14A automatic solvent degasser (Shimadzu), a SIL-10AD$_{VP}$ auto injector (Shimadzu), and a CTO-10AD$_{VP}$ column oven (Shimadzu) set to 40 °C. Separations were carried out using a CAPCELL PAK C18 UG120 (4.6 mm × 250 mm) with a solvent system consisting of an isocratic solvent A (methanol–0.1% acetic acid, 95:5, v/v) in 25 min and then a linear gradient from 0 to 50% ethanol in 50 min. Mass spectrometry was performed with an API3000 LC/MS/MS System (Applied Biosystems, Foster City, CA, USA), equipped with an APCI electrospray interface. All MS data were collected in positive ion mode. The following APCI/MS parameter settings were applied: corona discharge needle voltage, 4.5 kV; vaporizer temperature, 400 °C; sheath gas (high-purity nitrogen) pressure, 70 psi; no auxiliary gas; and transfer capillary temperature, 220 °C. The electron multiplier voltage was set at 850 eV. The scan range for the parent scan was 400–500 atomic mass units (amu) in case of PK, MK-4, and their ^{18}O-labeled compounds, 600–700 amu in MK-7 and ^{18}O-MK-7. Quantitative analysis was carried out using MS/MS-multiple reaction monitoring (MRM) of precursor ion of Vitamin K homologues (*m/z* 445, MK-4; 449, ^{18}O-MK-4; 451, PK; 455, ^{18}O-PK; 649, MK-7; 651, ^{18}O-MK-7) and their product ion (*m/z* 187, natural Vitamin Ks; 191, ^{18}O-labeled Vitamin Ks) with a dwell time of 500 ms. Calibration, using internal standardization, was done by linear regression analysis using four different concentration ranges from 12.5 to 200 ng/mL. The concentration of MK-4, PK and MK-7 in plasma was calculated as fluorescence detection.

3. Results and discussion

3.1. Optimal HPLC systems and internal standards

PK, MK-4 and MK-7 were detected in almost all plasma samples from healthy subjects tested here. In contrast, MK-5, MK-6, MK-8, MK-9 and MK-10 were not detected in all samples. Thus, it was decided to measure PK, MK-4 and MK-7 in this study using two kinds of HPLC systems. In case of determination of MK-4 in control serum and plasma of healthy subjects, MK-4 was not separated completely from interfering compounds in serum or plasma by a mixture of methanol and ethanol, which was used as mobile phase generally (data not shown). In addition, the peak which has retention times very close to that of MK-4 was observed during the analysis without reduction. To separate MK-4 from interfering compounds, HPLC System 1 (retention time of MK-4, 23.74 min) was used. In System 1, unknown peaks, which eluted at the same retention time as MK-4 was not observed with or without reduction column. For quantitative analysis of MK-4, I.S.-C16, which was found as a single peak, was chosen as an internal standard. The retention times of Vitamin K analogs in System 1 were as follows: I.S.-C13, 21.88 min; I.S.-C14, 27.41 min; I.S.-C15, 32.43 min; I.S.-C16, 41.98 min. Fig. 2 shows the chromatographic profiles of authentic MK-4 and I.S.-C16 (Fig. 2A), a representative plasma sample from healthy subject with post-column reduction (Fig. 2B) and the same plasma sample without post-column reduction (Fig. 2C) in System 1.

Utilizing a 95:5 (v/v) mixture of methanol and ethanol as mobile phase and the detection at 430 nm with excitation at 320 nm were effective for the separation of PK from other substances in serum or plasma, however, MK-7 was not



Fig. 2. Chromatograms of authentic standards and a plasma sample in System 1. (A) authentic standards of MK-4 and I.S.-C16; (B) a plasma sample obtained from a healthy subject with reduction by the platinum-reduction column; and (C) a plasma sample obtained from a healthy subject without reduction by the platinum-reduction column.



Fig. 3. Chromatograms of authentic standards and a plasma sample in System 2. (A) authentic standards of MK-4, PK, I.S.-C19 and MK-7; (B) a plasma sample obtained from the same subject as shown in Fig. 2 with reduction by the platinum-reduction column; and (C) a plasma sample obtained from the same subject as shown in Fig. 2 without reduction by the platinum-reduction column.

successfully isolated from deterrent. HPLC chromatograms were obtained by injecting plasma samples and verifying the excitation wavelength from 230 to 320 nm and the optimum excitation wavelength for the detection of PK and MK-7 was set at 240 nm (data not shown). For quantitative analysis of PK and MK-7 in System 2, I.S.-C19, which was found as a single peak between PK and MK-7, was chosen as an internal standard. The retention times of PK, MK-7 and Vitamin K analogs in System 2 were as follows: PK, 16.99 min; MK-7, 34.48 min; I.S.-C13, 11.47 min; I.S.-C14, 13.04 min; I.S.-C15, 15.42 min; I.S.-C16, 17.81 min; I.S.-C18, 24.41 min; I.S.-C19, 25.54 min; I.S.-C20, 31.01 min; I.S.-C23, 36.35 min. Fig. 3 shows the chromatographic profiles of authentic MK-4, PK, IS-C19 and MK-7 (Fig. 3A), a representative plasma sample from healthy subject with post-column reduction (Fig. 3B) and the same plasma sample without post-column reduction (Fig. 3C) in System 2. MK-4 was not separated from interfering compounds in plasma.

For multiple assay of MK-4, PK and MK-7, a gradient eluent system after elution of MK-4 is available. It has been

Table 1
The recoveries of MK-4, PK and MK-7

	MK-4	PK	MK-7
Low ($n=5$)			
Mean ± S.D. (%)	93 ± 8.6	103 ± 5.2	97 ± 6.1
R.S.D. (%)	9.2	5.0	6.3
Middle ($n=5$)			
Mean ± S.D. (%)	101 ± 2.5	99 ± 2.3	101 ± 4.6
R.S.D. (%)	2.5	2.3	4.6
High ($n=5$)			
Mean ± S.D. (%)	99 ± 5.2	99 ± 2.0	104 ± 3.2
R.S.D. (%)	5.3	2.0	3.1

Table 2
Intra- and inter-assay/R.S.D. values of assay method for Vitamin K

	MK-4	PK	MK-7
Intra-assay ($n = 10$)			
Control serum			
Mean ± S.D. (ng/mL)	0.179 ± 0.014	0.145 ± 0.014	0.067 ± 0.013
R.S.D. (%)	7.5	9.6	19.3
Plasma of normal subject			
Mean ± S.D. (ng/mL)	0.353 ± 0.021	1.270 ± 0.084	0.693 ± 0.061
R.S.D. (%)	6.0	6.6	8.8
Inter-assay ($n = 10$)			
Control serum			
Mean ± S.D. (ng/mL)	0.191 ± 0.011	0.152 ± 0.008	0.076 ± 0.011
R.S.D. (%)	5.7	5.3	13.9
Plasma of normal subject			
Mean ± S.D. (ng/mL)	0.332 ± 0.031	1.193 ± 0.058	0.598 ± 0.038
R.S.D. (%)	9.2	4.9	6.3

confirmed that MK-4, PK and MK-7 were successfully determined without interruption of co-eluting compounds by using following HPLC system; column, CAPCELL PAK C18 UG120 (4.6 mm × 250 mm); reduction column, RC-10 (4.0 mm × 15 mm); mobile phase, an isocratic elution of 95:5 (v/v) mixture of methanol and water for 30 min, and a linear gradient from 0 to 100% ethanol following 50 min; flow-rate, 1.0 mL/min; excitation wavelength, 240 nm; emission wavelength, 430 nm; retention time of MK-4, 23.74 min; I.S.-C16, 38.49 min; PK, 44.73 min; I.S.-C19, 55.12 min; MK-7, 65.79 min.

3.2. Sensitivity, precision and accuracy

A calibration curve of MK-4, PK and MK-7 gave a linearity between 2 and 500 pg in Systems 1 and 2 described previous section. The detection limits of MK-4 and MK-7, based on a signal-to-noise ratio of 3: 1, were 4 pg per injection, and that of PK was 2 pg per injection, respectively. The recoveries of MK-4, PK and MK-7 calculated by measurements of control serum spiked Vitamin K at low (MK-4, 0.1 ng; PK, 0.4 ng; MK-7, 0.75 ng/0.5 mL serum), middle (MK-4, 0.2 ng; PK, 0.8 ng; MK-7, 1.5 ng/0.5 mL serum) and high (MK-4, 0.4 ng; PK, 1.6 ng; MK-7, 3.0 ng/0.5 mL serum) concentration were about 92–105% (Table 1). Intra- and inter-assay R.S.D. values calculated by measurements of control serum and plasma of healthy subject were 5.73–9.21% for MK-4, 4.86–9.64% for PK and 6.32–19.31% for MK-7 (Table 2). We speculate that intra- and inter-assay R.S.D. values of control serum for MK-7 were high because concentration of MK-7 was low and close to the limit of quantitation. The sensitivity and an overall recovery combined with reproducibility allowed the measurement of three kinds of Vitamin K, MK-4, PK and MK-7 with only 0.2 mL of plasma, which is smaller than in previous.

3.3. Concentration of Vitamin K in healthy subjects and osteoporotic patients treated with MK-4

This method was applied to the plasma samples obtained from 20 healthy subjects and 10 osteoporotic patients. Plasma levels of MK-4, PK and MK-7 in healthy subjects were 0.15 ± 0.17 ng/mL (mean ± S.D.), 1.81 ± 1.10 ng/mL and 16.27 ± 20.58 ng/mL, respectively (Table 3). Plasma levels of MK-4, PK and MK-7 in osteoporotic patients treated with MK-4 were 46.83 ± 46.41 ng/mL, 0.62 ± 0.25 ng/mL and 4.18 ± 6.28 ng/mL, respectively. The plasma levels of MK-4 in patients treated with MK-4 were significantly higher than that of healthy subjects ($p < 0.05$). The plasma levels of PK and MK-7 in patients treated with MK-4 were significantly lower than that of healthy subjects ($p < 0.001$ and $p < 0.05$, respectively). However, it is conceivable that the individual difference derived from diet exists in plasma levels of PK and MK-7. We confirmed that the plasma concentration of MK-7 was markedly increased after intake of fermented soybean (data not shown).

Table 3
Concentration of Vitamin K in healthy subjects and osteoporotic patients treated with MK-4

	MK-4	PK	MK-7
Healthy subjects ($n = 20$) (mean ± S.D. (ng/mL))			
Fluorescence detection	0.149 ± 0.172	1.814 ± 1.107	16.27 ± 20.58
LC-APCI/MS detection	0.392 ± 0.457	2.163 ± 1.340	17.53 ± 22.55
Osteoporotic patients ($n = 10$) (mean ± S.D. (ng/mL))			
Fluorescence detection	46.83 ± 46.41	0.621 ± 0.245	4.179 ± 6.281
LC-APCI/MS detection	51.89 ± 44.88	0.850 ± 0.272	4.128 ± 6.373



Fig. 4. Correlation between the values obtained by HPLC with fluorescence detection using internal standards and those obtained by LC-APCI/MS. (A) MK-4; (B); PK; and (C) MK-7.

3.4. Correlation with LC-APCI/MS method

To compare the proposed method with LC-APCI/MS method, the same plasma samples of healthy subjects and osteoporotic patients treated with MK-4 were measured by both methods (Table 3). Fig. 4 shows correlation between the values obtained by HPLC with fluorescence detection using internal standards and those obtained by LC-APCI/MS. The data showed good correlation between two methods for MK-4 (Fig. 4A, $y=0.966x+1.181$, $R^2=0.988$), PK (Fig. 4B, $y=0.841x+0.035$, $R^2=0.979$) and MK-7 (Fig. 4C, $y=0.908x-0.386$, $R^2=0.986$), respectively. These results suggest that the accuracy of quantitative determination of Vitamin K by this method was sufficient for nutritional and clinical applications.

4. Conclusions

Here we show an improved HPLC method for determination of Vitamin K with fluorescence detection using post column reduction. Synthetic internal standards were synthesized and used and validated to quantify MK-4, PK and MK-7. The proposed method has several advantages in comparison with previously reported method: high selectivity and reproducibility attained by using two kinds of HPLC system optimized for determination of MK-4 and less polar derivatives, PK and MK-7; satisfactory precision and accuracy attained by using synthetic Vitamin K analogs as internal standards; small sample required for determination of three major Vitamin K derivatives, MK-4, PK and MK-7. Therefore, the proposed method is suitable for both clinical and nutritional studies and the routine assay for MK-4, PK and MK-7 in plasma. Due to its high sensitivity, the assay may provide a useful tool for elucidation of importance of Vitamin K in bone metabolism, for example, analysis of Vitamin K in bone tissue extracts obtained from animals.

Acknowledgements

We gratefully thank Dr. Masataka Shiraki, the Research Institute and Practice for Involutional Disease for providing plasma samples and Eisai Co. Ltd. for providing Vitamin K standards. We also thank Hiroko Takechi, Ai Mishima, Kaori Ishimaru, Masako Uwano and Noriko Yamaguchi for their excellent technical assistance. This work was supported in part by a Grant-in-aid for Comprehensive Research on Cardiovascular Diseases and the Research on the Dietary Reference Intakes in Japanese from the Ministry of Health, Labor and Welfare of Japan.

References

[1] P.A. Friedman, N. Engl. J. Med. 310 (1984) 1458.
[2] P.M. Gallop, J.B. Lian, P.V. Hauschka, N. Engl. J. Med. 302 (1980) 1460.
[3] Y. Sato, Y. Honda, H. Kuno, K. Oizumi, Bone 23 (1998) 291.
[4] I. Iwamoto, S. Kosha, S. Noguchi, M. Murakami, T. Fujino, T. Douchi, Y. Nagata, Maturitas 31 (1999) 161.
[5] A.M. Craciun, J. Wolf, M.H. Knapen, F. Brouns, C. Vermeer, Int. J. Sports Med. 19 (1998) 479.
[6] Y. Somekawa, M. Chigughi, M. Harada, T. Ishibashi, J. Clin. Endocrinol. Metab. 84 (1999) 2700.
[7] Y. Akiyama, K. Hara, I. Ohkawa, T. Tajima, Jpn. J. Pharmacol. 62 (1993) 145.
[8] K. Hara, Y. Akiyama, I. Ohkawa, T. Tajima, Bone 14 (1993) 813.
[9] T. Tomiuga, M. Kobayashi, Y. Nakajima, M. Bessho, Y. Katoh, K. Hara, Y. Akiyama, T. Nakamura, T. Tajima, Jpn. J. Pharmacol. 65 (1994) 35.
[10] Y. Ehara, H. Takahashi, Y. Hanahisa, M. Yamaguchi, Res. Exp. Med. (Berl.) 196 (1996) 171.
[11] Y. Akiyama, K. Hara, M. Kobayashi, T. Tomiuga, T. Nakamura, Jpn. J. Pharmacol. 80 (1999) 67.
[12] S. Matsunaga, H. Ito, T. Sakou, Calcif. Tissue Int. 65 (1999) 285.

[13] M. Yamaguchi, H. Taguchi, Y.H. Gao, A. Igarashi, Y. Tsukamoto, J. Bone Miner. Metab. 17 (1999) 23.
[14] M.J. Shearer, Blood Rev. 6 (1992) 92.
[15] J.W. Suttie, J. Am. Diet Assoc. 92 (1992) 585.
[16] S.J. Hodges, M.J. Pilkington, M.J. Shearer, L. Bitensky, J. Chayen, Clin. Sci. 78 (1990) 63.
[17] P.L. Donnahey, V.T. Burt, H.H. Rees, J. Chromatogr. 170 (1979) 272.
[18] G.H. Dialameh, R.E. Olson, Anal. Biochem. 32 (1969) 263.
[19] G.G. Dolnikowski, Z. Sun, M.A. Grusak, J.W. Peterson, S.L. Booth, J. Nutr. Biochem. 13 (2002) 168.
[20] E.M. Kirk, A.F. Fell, Clin. Chem. 35 (1989) 1288.
[21] T. Sakano, T. Nagaoka, A. Morimoto, K. Hirauchi, Chem. Pharm. Bull. 34 (1986) 4322.
[22] Y. Haroon, D.S. Bacon, J.A. Sadowski, J. Chromatogr. 384 (1987) 383.
[23] M. Shino, Analyst 113 (1988) 393.
[24] Y. Usui, N. Nishimura, N. Kobayashi, T. Okanoue, M. Kimoto, K. Ozawa, J. Chromatogr. 489 (1989) 291.
[25] K. Hirauchi, T. Sakano, S. Notsumoto, T. Nagaoka, A. Morimoto, K. Fujimoto, S. Masuda, Y. Suzuki, J. Chromatogr. 497 (1989) 131.
[26] J.P. Hart, M.J. Shearer, P.T. McCarthy, S. Rahim, Analyst 109 (1984) 477.
[27] Y. Haroon, C.A. Schubert, P.V. Hauschka, J. Chromatogr. Sci. 22 (1984) 89.
[28] J.P. Hart, M.J. Shearer, P.T. McCarthy, Analyst 110 (1985) 1181.
[29] H. Wakabayashi, K. Onodera, S. Yamato, K. Shimada, Nutrition 19 (2000) 661.
[30] Y. Sano, K. Kikuchi, K. Tadano, K. Hoshi, Y. Koshihara, Anal. Sci. 13 (1997) 67.
[31] Y. Suhara, M. Kamao, N. Tsugawa, T. Okano, Anal. Chem., in press.
[32] K.W. Devidson, J.A. Sadowski, Methods Enzymol. 282 (1997) 408.
[33] L. Benli, G. Lianzuan, Z. Jingling, Recl. Trav. Chim. Pays-Bas 110 (1991) 99.

Lymphocyte and Plasma Vitamin C Levels in Type 2 Diabetic Patients With and Without Diabetes Complications

HIROSHI YAMADA, MD[1]
KAORU YAMADA, MD[2]
MASAKO WAKI, MD[3]
KEIZO UMEGAKI, PHD[4]

Diabetes has been considered to be associated with oxidative stress. It has been suggested that increased free radicals and decline of antioxidant defense mechanisms induce diabetic micro- and macrovascular complications (1–3). Vitamin C is one of the major antioxidants and is detected in various blood components (4). However, measurements of vitamin C levels have shown inconsistent results, and the interpretation of vitamin C levels in diabetes as an antioxidant biomarker has not been clarified (5–8). In this study, we investigated the lymphocyte and plasma vitamin C levels in type 2 diabetic patients with and without diabetes complications.

RESEARCH DESIGN AND METHODS — Forty-one patients with type 2 diabetes (63 ± 8.9 years [mean ± SD]; 25 men and 16 women) attending the Department of Endocrinology and Metabolism at Shizuoka City Hospital were recruited. Type 2 diabetes was diagnosed according to the American Diabetes Association criteria. The duration of illness was 11 ± 8.3 years, fasting plasma glucose was 137 ± 43 mg/dl, and HbA_{1c} levels were 7.1 ± 1.0%. Twenty-six patients had diabetes complications with neuropathy, retinopathy, or nephropathy, and 15 patients had no complications. Both diabetic groups were matched by age, sex, fasting plasma glucose, and HbA_{1c} level (63 ± 9.7 years, 18 men and 8 women, 137 ± 45 mg/dl, and 7.2 ± 1.0% for diabetic patients with complications compared with 64 ± 7.5 years, 7 men and 8 women, 137 ± 42 mg/dl, and 6.8 ± 0.8% for diabetic patients without complications, respectively). The duration of illness was longer in the diabetic patients with complications than in diabetic patients without complications (13 ± 9.1 vs. 7.7 ± 5.2 years, respectively, $P = 0.051$). For the normal control subjects, 50 age- and sex-matched healthy volunteers (63 ± 5.7 years, 31 men and 19 women) were recruited. The participants taking vitamin supplements were excluded from the study. All participants gave informed consent before entering the study. The study was conducted in accordance with the Declaration of Helsinki and was approved by the ethics committee at the hospital.

Blood samples were obtained by vein puncture in the morning while the patients were in the fasting state. Lymphocytes and plasma were prepared by centrifugation and the Ficoll gradients method, then immediately treated with metaphosphoric acid (final 5% wt/wt) to stabilize vitamin C (9,10). These processes were performed within 2 h under cooled conditions on ice to obtain reliable data. The vitamin C samples were stored at −80°C until analyzed, and the vitamin C (ascorbic acid, reduced form) levels were measured by high-performance liquid chromatography with the electrochemical detector method (11). All samples were handled and stored similarly in both diabetic patients and control subjects.

The lymphocyte and plasma vitamin C levels in type 2 diabetic patients were compared with those of the control subjects. The differences between the vitamin C levels in type 2 diabetic patients with and without diabetes complications were also studied. Statistical analysis was performed with the unpaired Student's *t* test to compare the data between diabetic patients and control subjects and between type 2 diabetic patients with and without diabetes complications. A P value <0.05 was considered significant.

RESULTS — The lymphocyte vitamin C level in diabetic patients was significantly lower than in control subjects (18 ± 4.5 vs. 28 ± 7.9 nmol/mg protein, $P < 0.0001$), whereas the plasma vitamin C level was not different (59 ± 19 vs. 53 ± 18 μmol/l, $P = 0.17$) (Fig. 1*A* and *B*). There were no significant linear correlations between the lymphocyte and plasma vitamin C levels in diabetic patients ($r = 0.011$, $P = 0.95$) as well as in control subjects ($r = 0.14$, $P = 0.35$). The lymphocyte vitamin C level in diabetic patients with complications was significantly lower than in those without complications (17 ± 3.3 vs. 21 ± 5.4 nmol/mg protein, $P = 0.011$) (Fig. 1*C*), whereas the plasma vitamin C level was not different (59 ± 18 vs. 59 ± 21 μmol/l, $P = 0.97$).

CONCLUSIONS — Increased oxidative stress in diabetes could contribute to depletion of antioxidants such as vitamin C (2,3). In this report, we demonstrated that the lymphocyte vitamin C level is significantly lower in type 2 diabetic patients, but we could not observe such an association in plasma vitamin C levels. The plasma concentration of vitamin C is considered to be strongly correlated with transient consumption of foods such as fruit, supplements, and vegetables (4).

From the [1]General Clinical Research Center, Hamamatsu University School of Medicine, Hamamatsu, Japan; the [2]Department of Health and Preventive Care Center, Shizuoka City Hospital, Shizuoka, Japan; the [3]Department of Endocrinology and Metabolism, Shizuoka City Hospital, Shizuoka, Japan; and the [4]National Institute of Health and Nutrition, Toyama, Shinjuku-ku, Tokyo, Japan.

Address correspondence and reprint requests to Dr. Hiroshi Yamada, MD, Hamamatsu University School of Medicine, General Clinical Research Center, 1-20-1 Handayama, Hamamatsu 431-3192, Japan. E-mail: hyamada@hama-med.ac.jp.

Received for publication 4 June 2004 and accepted in revised form 28 June 2004.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.



Figure 1—*Lymphocyte and plasma vitamin C levels in type 2 diabetic patients* (n = *41*) *and control subjects* (n = *50*). A: *Lymphocyte vitamin C level in diabetic patients was significantly lower than that in the control subjects* (**P < *0.0001*). B: *Plasma vitamin C level in diabetic patients was not different from that in the control subjects* (P = *0.17*). C: *Lymphocyte vitamin C level in diabetic patients with complications* (n = *26*) *was significantly lower than that in those without complications* (n = *15*) (*P = *0.011*). *The horizontal bars represent the mean ± SD.*

Compared with plasma, lymphocyte has been reported to maintain a vitamin C concentration as large as 80- to 100-fold across the plasma membrane (12,13) and to have cell-membrane transporting mechanisms between vitamin C and glucose (14,15). In diabetes, therefore, the measurement of lymphocyte vitamin C might be expected to be a more reliable antioxidant biomarker than plasma vitamin C level.

It is unclear whether leukocyte vitamin C correlates with diabetes complications. VanderJagt et al. (5) reported that vitamin C levels in mononuclear leukocytes were decreased in the whole group of type 1 diabetic patients compared with control subjects but were not different between patients with and without long-term complications. We showed the significant lower lymphocyte vitamin C levels in patients with type 2 diabetes with complications compared with those without complications. However, the results should be interpreted carefully because of the small sample size and because the differences of lymphocyte vitamin C level among different diabetes complications are not fully clarified. Further studies are required to investigate the precise correlations of lymphocyte vitamin C with duration or severity of diabetes and to establish the clinical usefulness of lymphocyte vitamin C level as a biomarker in developing diabetes complications.

Acknowledgments— This study was supported by a grant from Japanese Ministry of Health, Labour and Welfare.

We thank Reiko Akiyama for her skillful assistance.

References

1. Giugliano D, Ceriello A, Paolisso G: Oxidative stress and diabetic vascular complications. *Diabetes Care* 19:257–267, 1996
2. Maritim AC, Sanders RA, Watkins JB 3rd: Diabetes, oxidative stress, and antioxidants: a review. *J Biochem Mol Toxicol* 17: 24–38, 2003
3. Hasanain B, Mooradian AD: Antioxidant vitamins and their influence in diabetes mellitus. *Curr Diab Rep* 2:448–456, 2002
4. Omaye ST, Schaus EE, Kutnink MA, Hawkes WC: Measurement of vitamin C in blood components by high-performance liquid chromatography: implication in assessing vitamin C status. *Ann N Y Acad Sci* 498:389–401, 1987
5. VanderJagt DJ, Harrison JM, Ratliff DM, Hunsaker LA, Vander Jagt DL: Oxidative stress indices in IDDM subjects with and without long-term diabetic complications. *Clin Biochem* 34:265–270, 2001
6. Cunningham JJ, Ellis SL, McVeigh KL, Levine RE, Calles-Escandon J: Reduced mononuclear leukocyte ascorbic acid content in adults with insulin-dependent diabetes mellitus consuming adequate dietary vitamin C. *Metabolism* 40:146–149, 1991
7. Sinclair AJ, Taylor PB, Lunec J, Girling AJ, Barnett AH: Low plasma ascorbate levels in patients with type 2 diabetes mellitus consuming adequate dietary vitamin C. *Diabet Med* 11:893–898, 1994
8. Schorah CJ, Bishop N, Wales JK, Hansbro PM, Habibzadeh N: Blood vitamin C concentrations in patients with diabetes mellitus. *Int J Vitam Nutr Res* 58:312–318, 1988
9. Margolis SA, Davis TP: Stabilization of ascorbic acid in human plasma, and its liquid-chromatographic measurement. *Clin Chem* 34:2217–2223, 1988
10. Umegaki K, Yoshimura M, Nishimuta M, Esashi T: A practical method for determination of vitamin C in plasma by high-performance liquid chromatography with an electrochemical detector. *J Jpn Soc Nutr Food Sci* 2:107–111, 1999
11. Washko PW, Hartzell WO, Levine M: Ascorbic acid analysis using high-performance liquid chromatography with coulometric electrochemical detection. *Anal Biochem* 181:276–282, 1989
12. Bergsten P, Amitai G, Kehrl J, Dhariwal KR, Klein HG, Levine M: Millimolar concentrations of ascorbic acid in purified human mononuclear leukocytes: depletion and reaccumulation. *J Biol Chem* 265: 2584–2587, 1990
13. Evans RM, Currie L, Campbell A: The distribution of ascorbic acid between various cellular components of blood, in normal individuals, and its relation to the plasma concentration. *Br J Nutr* 47:473–482, 1982
14. Bergsten P, Yu R, Kehrl J, Levine M: Ascorbic acid transport and distribution in human B lymphocytes. *Arch Biochem Biophys* 317:208–214, 1995
15. Ngkeekwong FC, Ng LL: Two distinct uptake mechanisms for ascorbate and dehydroascorbate in human lymphoblasts and their interaction with glucose. *Biochem J* 324:225–230, 1997

オボアルブミン誘発食物アレルギー発症に対する高ビタミンE食投与の影響

兼安 真弓[1]　吉村 寛幸[2]　森口 覚[1]

山口県立大学大学院　健康福祉学研究科　生活健康科学専攻[1]
エーザイフード・ケミカル株式会社[2]

はじめに

近年、我が国では食物アレルギー、アトピー性皮膚炎、花粉症などのアレルギー疾患を持つ人が著明に増加しており問題となっている。その原因として、高蛋白・高栄養な食生活や、大気汚染、花粉、ダニなどのアレルゲンの増加、社会的ストレスの増加など多くの要因の関与が考えられている。最近、ヒトおよび実験動物において高ビタミンE(VE)摂取がアレルギーの発症、進展に対して有益な効果をもたらすことが見出され、その効果が期待されている[1)-3)]。本研究では、オボアルブミン(OVA)誘発食物アレルギーモデルマウスを用いてアレルギー発症に対する高VE食投与の影響について検討した。また、これまでの報告のほとんどはVEとしてα-トコフェロール(α-Toc)を用いているが、今回の実験ではα-Tocに加えてγ-トコトリエノール(γ-T3)の抗アレルギー作用についても併せて検討を行った。

方法

実験動物としてBALB/cマウス、雌、8週齢を用いた。1週間予備飼育後、Halterenら[4)]の方法により実験開始時にOVA 2μgと水酸化アルミニウムゲル(ALUM)25μlを腹腔内投与し、さらに14日目にOVA 1μgを腹腔内投与後、18日目にOVA 1 mgを経口投与することにより食物アレルギーモデルマウスを作成した(図1)。



図1 食物アレルギーモデルマウスの作成

実験期間中、コントロール群は標準食(50mg α-Toc/kg)にて飼育した。VE 添加食群は 2 回目の感作までは標準食を与え、その後から標準食にα-Toc またはγ-T3 を 200 または 450 mg/kg 添加した食餌を与えた。実験期間中の摂食量および体重については週 1 回測定し、OVA 経口投与の 4 日後の 22 日目に採血し、脾臓を摘出した。採取した血液から血清を分離し、血清総 IgE および OVA 特異的 IgE 濃度を ELISA 法により測定した。免疫能として、Con A、PHA 等のマイトジェンおよび OVA 刺激による脾臓リンパ球幼若化能、ヘルパーT(CD4)およびサプレッサーT(CD8)細胞割合、Con A 刺激48時間後の脾臓リンパ球培養上清中のインターロイキン4(IL-4)濃度について検討した。

結果

1. 体重、脾臓重量ならびに脾臓リンパ球数

実験期間中の摂食量については、α-Toc およびγ-T3 投与の影響はみられず、コントロール群と各 VE 添加食群との間に差異を認めなかった。体重、脾臓重量および脾臓リンパ球数についても、コントロール群と各 VE 添加食群との間に有意な差異を認めなかった(表 1)。

表 1 体重、脾臓重量ならびに脾臓リンパ球数

Groups	Body wt. (g)	Spleen wt. (g/100g BW)	Splenic lymphocytes no. (10^{-7}/0.1g spleen)
Control	23.5±0.6	0.46±0.03	3.44±0.36
200mg/kg α-Toc	23.3±0.2	0.43±0.03	3.47±0.40
450mg/kg α-Toc	24.5±0.5	0.41±0.01	3.63±0.13
200mg/kg γ-T3	24.3±1.2	0.36±0.03	2.44±0.36
450mg/kg γ-T3	24.3±0.5	0.41±0.02	3.05±0.44

2. 血清総 IgE および OVA 特異的 IgE 濃度

血清総 IgE 濃度は、コントロール群と比較し 450 mg/kg α-Toc 添加食群において低い傾向を認めたものの、γ-T3 添加食群については変化を認めなかった(図 2)。



図 2 血清総 IgE 濃度

血清 OVA 特異的 IgE 濃度は、コントロール群と比較し 200 mg/kg α-Toc 添加食群においては低い傾向を認め、さらに 450 mg/kg α-Toc 添加食群においては有意な低下を認めた。また、450 mg/kg γ-T3 添加食群の血清 OVA 特異的 IgE 濃度は、コントロール群と比較してやや低い傾向を認めた(図 3)。



図 3 血清 OVA 特異的 IgE 濃度

3. 脾臓リンパ球幼若化能

Con A および PWM 刺激に対する脾臓リンパ球幼若化能は、コントロール群と比較し各 VE 添加食群において高い傾向を認めた。しかし、PHA および LPS 刺激に対する脾臓リンパ球幼若化能は、コントロール群と比較し 450 mg/kg α-Toc 添加食群において逆に低い傾向を認めた。一方、OVA 刺激に対する脾臓リンパ球幼若化能は、コントロール群と比較し 450 mg/kg α-Toc 添加食群において有意に高いことを認めた(図 4)。



図 4 脾臓リンパ球幼若化能